These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 1462990)

  • 1. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study.
    Grino JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Mestre M; Torras J; Alsina J
    Am J Kidney Dis; 1992 Dec; 20(6):603-10. PubMed ID: 1462990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.
    Hanto DW; Jendrisak MD; So SK; McCullough CS; Rush TM; Michalski SM; Phelan D; Mohanakumar T
    Transplantation; 1994 Feb; 57(3):377-84. PubMed ID: 8108873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antilymphocyte globulin with a small dose of cyclosporine A and prednisone as the induction of immunosuppression in renal allograft recipients.
    Boratyńska M; Szepietowski T; Szewczyk Z; Szydłowski Z
    Arch Immunol Ther Exp (Warsz); 1992; 40(2):163-8. PubMed ID: 1299176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antilymphocyte globulins versus OKT3 as prophylactic treatment in highly sensitized renal transplant recipients.
    Vela C; Cristol JP; Chong G; Okamba A; Lorho R; Mion C; Mourad G
    Transpl Int; 1994; 7 Suppl 1():S259-62. PubMed ID: 11271219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antilymphocyte serum, cyclosporine and corticoids, versus OKT3, cyclosporine, and corticoids in kidney transplantation].
    Grino JM; Castelao AM; Seron D; Gonzalez C; Gil-Vernet S; Andres E; Bover J; Mestre M; Alsina J
    Presse Med; 1991 Nov; 20(40):2039-42. PubMed ID: 1837121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective randomized controlled trial of initial immunosuppression with ALG versus OKT3 in recipients of cardiac allografts.
    Menkis AH; Powell AM; Novick RJ; McKenzie FN; Kostuk WJ; Pflugfelder PW; Brown JE; Rochon J; Chow LH; Stiller C
    J Heart Lung Transplant; 1992; 11(3 Pt 1):569-76. PubMed ID: 1610866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic OKT3, CyA, and steroids versus antilymphoblast globulin, CyA, and steroids in cadaveric kidney transplantation.
    Griñó JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Bover J; Torras J; Alsina J
    Transplant Proc; 1992 Feb; 24(1):39-41. PubMed ID: 1539329
    [No Abstract]   [Full Text] [Related]  

  • 8. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients.
    Mariat C; Alamartine E; Diab N; de Filippis JP; Laurent B; Berthoux F
    Transpl Int; 1998; 11(3):231-6. PubMed ID: 9638854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antilymphoblast globulin, cyclosporine, and steroids in cadaveric renal transplantation.
    Griño JM; Alsina J; Sabater R; Castelao AM; Gil-Vernet S; Andres E; Sabate I; Mestre M; Seron D; Diaz C
    Transplantation; 1990 Jun; 49(6):1114-7. PubMed ID: 2360253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
    Cantarovich M; Latter DA; Loertscher R
    Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OKT3 for primary therapy of the first rejection episode in kidney transplants.
    Tesi RJ; Elkhammas EA; Henry ML; Ferguson RM
    Transplantation; 1993 May; 55(5):1023-9. PubMed ID: 8497875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective randomized comparison of quadruple versus triple therapy for first cadaver transplants with immediate function.
    Slakey DP; Johnson CP; Callaluce RD; Browne BJ; Zhu YR; Roza AM; Adams MB
    Transplantation; 1993 Oct; 56(4):827-31. PubMed ID: 8212201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective randomized study of prophylactic OKT3 versus equine antithymocyte globulin after heart transplantation--increased morbidity with OKT3.
    Macdonald PS; Mundy J; Keogh AM; Chang VP; Spratt PM
    Transplantation; 1993 Jan; 55(1):110-6. PubMed ID: 8380508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of rabbit antithymocyte serum and OKT3 as prophylaxis against renal allograft rejection.
    Cole EH; Cattran DC; Farewell VT; Aprile M; Bear RA; Pei YP; Fenton SS; Tober JA; Cardella CJ
    Transplantation; 1994 Jan; 57(1):60-7. PubMed ID: 8291115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effect of concomitant induction with antilymphoblast globulin, cyclosporine, and steroids on long-term renal allograft outcome.
    Koga A; Moreso FJ; Seron D; Gil-Vernet S; Cruzado JM; Castelao AM; Grinyó JM
    Transplant Proc; 2004 Jun; 36(5):1305-7. PubMed ID: 15251318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of OKT3 with ALG for prophylaxis for patients with acute renal failure after cadaveric renal transplantation.
    Steinmuller DR; Hayes JM; Novick AC; Streem SB; Hodge E; Slavis S; Martinez A; Graneto D; Pearce G
    Transplantation; 1991 Jul; 52(1):67-71. PubMed ID: 1677502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential antilymphocyte globulin/cyclosporine immunosuppression in cadaveric renal transplantation. Effect of duration of ALG therapy.
    Stratta RJ; D'Alessandro AM; Armbrust MJ; Pirsch JD; Sollinger HW; Kalayoglu M; Belzer FO
    Transplantation; 1989 Jan; 47(1):96-102. PubMed ID: 2643236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G; Walsh G; Deshpande P; Koffman G
    Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosuppressive treatment of primary cadaveric renal transplant patients receiving kidneys from non-heart beating donors.
    Ohshima S; Fujita T; Ono Y; Kinukawa T; Katoh N; Matsuura O
    Artif Organs; 1996 Oct; 20(10):1130-6. PubMed ID: 8896734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation?
    Mozes MF; Venkat KK; Kupin W; Dumler F; Gracida C; Uniewski M; Anaise D; Tang DH
    Transplant Proc; 1993 Feb; 25(1 Pt 1):575-6. PubMed ID: 8438420
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.